PETMED EXPRESS, INC. Revenue
PETMED EXPRESS, INC. (PETS) reported Revenue of $41.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $41.02M, a 19.86% decline year-over-year.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $42.82M, a 15.65% decline year-over-year.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $40.66M, a 21.75% decline year-over-year.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $44.36M, a 23.57% decline year-over-year.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2026 was $179.02M, a 21.13% decline from fiscal 2025.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $226.97M, a 17.19% decline from fiscal 2024.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $274.10M, a 10.71% increase from fiscal 2023.
- PETMED EXPRESS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $247.57M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $41.02M 10-Q · filed 2026-08-13 | $83.83M derived: sum of 2 quarters · filed 2026-08-13 | $124.49M derived: sum of 3 quarters · filed 2026-08-13 | $168.86M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $42.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-02 | $83.48M derived: sum of 2 quarters · filed 2026-06-02 | $127.84M derived: sum of 3 quarters · filed 2026-06-02 | $179.02M 10-K · filed 2026-06-02 | |||
| 2025-12-31 | $40.66M 10-Q · filed 2026-02-05 | $85.02M derived: sum of 2 quarters · filed 2026-02-05 | $136.20M 10-Q · filed 2026-02-05 | $186.96M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-09-30 | $44.36M 10-Q · filed 2025-12-19 | $95.54M 10-Q · filed 2025-12-19 | $146.30M derived: sum of 3 quarters · filed 2026-08-13 | $198.26M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $51.18M 10-Q · filed 2026-08-13 | $101.94M derived: sum of 2 quarters · filed 2026-08-13 | $153.90M derived: sum of 3 quarters · filed 2026-08-13 | $211.94M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $50.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-02 | $102.72M derived: sum of 2 quarters · filed 2026-06-02 | $160.76M derived: sum of 3 quarters · filed 2026-06-02 | $226.97M 10-K · filed 2026-06-02 | |||
| 2024-12-31 | $51.96M 10-Q · filed 2026-02-05 | $52.98M 10-Q · filed 2025-02-10 | $110.00M derived: sum of 2 quarters · filed 2026-02-05 | $176.21M 10-Q · filed 2026-02-05 | $180.51M 10-Q · filed 2025-02-10 | $241.27M derived: sum of 4 quarters · filed 2026-06-02 | |
| 2024-09-30 | $58.04M 10-Q · filed 2025-12-19 | $59.57M 10-Q · filed 2024-11-07 | $124.25M 10-Q · filed 2025-12-19 | $127.52M 10-Q · filed 2024-11-07 | $189.31M derived: sum of 3 quarters · filed 2026-06-02 | $252.98M derived: sum of 4 quarters · filed 2026-06-02 | |
| 2024-06-30 | $66.21M 10-Q · filed 2025-12-19 | $67.95M 10-Q · filed 2024-08-07 | $131.26M derived: sum of 2 quarters · filed 2026-06-02 | $194.93M derived: sum of 3 quarters · filed 2026-06-02 | $264.39M derived: sum of 4 quarters · filed 2026-06-02 | ||
| 2024-03-31 | $65.05M derived: 10-K 12 month − 10-K 9 month · filed 2026-06-02 | $128.73M derived: sum of 2 quarters · filed 2026-06-02 | $198.18M derived: sum of 3 quarters · filed 2026-06-02 | $274.10M 10-K · filed 2026-06-02 | |||
| 2023-12-31 | $63.67M 10-K · filed 2025-10-14 | $65.32M 10-Q · filed 2025-02-10 | $133.13M derived: sum of 2 quarters · filed 2025-10-14 | $209.04M 10-K · filed 2025-10-14 | $214.56M 10-Q · filed 2025-02-10 | $268.83M derived: sum of 4 quarters · filed 2025-10-14 | |
| 2023-09-30 | $69.46M 10-K · filed 2025-10-14 | $71.00M 10-Q · filed 2024-11-07 | $145.37M 10-K · filed 2025-10-14 | $149.24M 10-Q · filed 2024-11-07 | $205.16M derived: sum of 3 quarters · filed 2025-10-14 | $262.39M derived: sum of 4 quarters · filed 2025-10-14 | |
| 2023-06-30 | $75.91M 10-K · filed 2025-10-14 | $78.24M 10-Q · filed 2024-08-07 | $135.70M derived: sum of 2 quarters · filed 2025-10-14 | $192.94M derived: sum of 3 quarters · filed 2025-10-14 | $256.09M derived: sum of 4 quarters · filed 2025-10-14 | ||
| 2023-03-31 | $59.79M derived: 10-K 12 month − 10-K 9 month · filed 2025-10-14 | $117.03M derived: sum of 2 quarters · filed 2025-10-14 | $180.18M derived: sum of 3 quarters · filed 2025-10-14 | $247.57M 10-K · filed 2025-10-14 | |||
| 2022-12-31 | $57.24M 10-K · filed 2025-10-14 | $120.39M derived: sum of 2 quarters · filed 2025-10-14 | $187.78M 10-K · filed 2025-10-14 | ||||
| 2022-09-30 | $63.16M 10-K · filed 2025-10-14 | $130.54M 10-K · filed 2025-10-14 | |||||
| 2022-06-30 | $67.39M 10-K · filed 2025-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVS HEALTH Corp (CVS) | United States | $108.783B | 27.06 |